{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:25:31Z","timestamp":1740108331455,"version":"3.37.3"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81503156","81601347"],"award-info":[{"award-number":["81503156","81601347"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Public Welfare Research and Capacity Building Fund of Guangdong","award":["2016A020218006"],"award-info":[{"award-number":["2016A020218006"]}]},{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2014A030310096"],"award-info":[{"award-number":["2014A030310096"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1007\/s00228-018-2584-4","type":"journal-article","created":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T14:55:51Z","timestamp":1541084151000},"page":"363-369","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Prediction of mizoribine pharmacokinetic parameters by serum creatinine in renal transplant recipients"],"prefix":"10.1007","volume":"75","author":[{"given":"Pan","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Longshan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingjing","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingjie","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Changxi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,11,1]]},"reference":[{"issue":"2","key":"2584_CR1","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1046\/j.1328-8067.2002.01536.x","volume":"44","author":"S Yokota","year":"2002","unstructured":"Yokota S (2002) Mizoribine: mode of action and effects in clinical use. Pediatr Int 44(2):196\u2013198","journal-title":"Pediatr Int"},{"issue":"1","key":"2584_CR2","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.transproceed.2016.10.018","volume":"49","author":"Y Shi","year":"2017","unstructured":"Shi Y, Liu H, Chen XG, Shen ZY (2017) Comparison of mizoribine and mycophenolate mofetil with a tacrolimus-based immunosuppressive regimen in living-donor kidney transplantation recipients: a retrospective study in China. Transplant Proc 49(1):26\u201331. \n                    https:\/\/doi.org\/10.1016\/j.transproceed.2016.10.018","journal-title":"Transplant Proc"},{"issue":"7\u20138","key":"2584_CR3","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/j.clinbiochem.2014.01.014","volume":"47","author":"S Xing","year":"2014","unstructured":"Xing S, Yang J, Zhang X, Zhou P (2014) Comparative efficacy and safety of mizoribine with mycophenolate mofetil for Asian renal transplantation--a meta-analysis. Clin Biochem 47(7\u20138):663\u2013669. \n                    https:\/\/doi.org\/10.1016\/j.clinbiochem.2014.01.014","journal-title":"Clin Biochem"},{"issue":"4","key":"2584_CR4","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1111\/j.1432-2277.2004.00042.x","volume":"18","author":"D Liu","year":"2005","unstructured":"Liu D, Kobayashi T, Nagasaka T, Yokoyama I, Ma Y, Miwa Y, Kuzuya T, Morozumi K, Oikawa T, Shimano Y, Takeuchi O, Uchida K, Nakao A (2005) Potential value of high-dose mizoribine as rescue therapy for ongoing acute humoral rejection. Transpl Int 18(4):401\u2013407. \n                    https:\/\/doi.org\/10.1111\/j.1432-2277.2004.00042.x","journal-title":"Transpl Int"},{"issue":"4","key":"2584_CR5","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1111\/j.1742-7843.2009.00489.x","volume":"106","author":"T Naito","year":"2010","unstructured":"Naito T, Tokashiki S, Mino Y, Otsuka A, Ozono S, Kagawa Y, Kawakami J (2010) Impact of concentrative nucleoside transporter 1 gene polymorphism on oral bioavailability of mizoribine in stable kidney transplant recipients. Basic Clin Pharmacol Toxicol 106(4):310\u2013316. \n                    https:\/\/doi.org\/10.1111\/j.1742-7843.2009.00489.x","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"5","key":"2584_CR6","doi-asserted-by":"publisher","first-page":"538","DOI":"10.2133\/dmpk.DMPK-11-NT-040","volume":"26","author":"M Fukao","year":"2011","unstructured":"Fukao M, Ishida K, Sakamoto T, Taguchi M, Matsukura H, Miyawaki T, Hashimoto Y (2011) Effect of genetic polymorphisms of SLC28A1, ABCG2, and ABCC4 on bioavailability of mizoribine in healthy Japanese males. Drug Metab Pharmacokinet 26(5):538\u2013543","journal-title":"Drug Metab Pharmacokinet"},{"issue":"1","key":"2584_CR7","doi-asserted-by":"publisher","first-page":"75","DOI":"10.2133\/dmpk.DMPK-12-NT-043","volume":"28","author":"K Ishida","year":"2013","unstructured":"Ishida K, Fukao M, Watanabe H, Taguchi M, Miyawaki T, Matsukura H, Uemura O, Zhang Z, Unadkat JD, Hashimoto Y (2013) Effect of salt intake on bioavailability of mizoribine in healthy Japanese males. Drug Metab Pharmacokinet 28(1):75\u201380","journal-title":"Drug Metab Pharmacokinet"},{"issue":"5","key":"2584_CR8","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1007\/s10157-016-1353-x","volume":"21","author":"T Nagai","year":"2017","unstructured":"Nagai T, Uemura O, Kaneda H, Ushijima K, Ohta K, Gotoh Y, Satomura K, Shimizu M, Fujieda M, Morooka M, Yamada T, Yamada M, Wada N, Hashimoto Y (2017) The true distribution volume and bioavailability of mizoribine in children with chronic kidney disease. Clin Exp Nephrol 21(5):884\u2013888. \n                    https:\/\/doi.org\/10.1007\/s10157-016-1353-x","journal-title":"Clin Exp Nephrol"},{"issue":"5","key":"2584_CR9","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1111\/j.1399-0012.2006.00522.x","volume":"20","author":"A Sugitani","year":"2006","unstructured":"Sugitani A, Kitada H, Ota M, Yoshida J, Doi A, Hirakata H, Tanaka M (2006) Revival of effective and safe high-dose mizoribine for the kidney transplantation. Clin Transpl 20(5):590\u2013595. \n                    https:\/\/doi.org\/10.1111\/j.1399-0012.2006.00522.x","journal-title":"Clin Transpl"},{"issue":"6","key":"2584_CR10","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1111\/j.1442-200X.2012.03733.x","volume":"54","author":"T Fuke","year":"2012","unstructured":"Fuke T, Abe Y, Hibino S, Takeshi M, Saito T, Sakurai S, Watanabe S, Murayama J, Itabashi K, Nakano Y (2012) Mizoribine requires individual dosing due to variation of bioavailability. Pediatr Int 54(6):885\u2013891. \n                    https:\/\/doi.org\/10.1111\/j.1442-200X.2012.03733.x","journal-title":"Pediatr Int"},{"issue":"6","key":"2584_CR11","first-page":"3643","volume":"28","author":"K Sonda","year":"1996","unstructured":"Sonda K, Takahashi K, Tanabe K, Funchinoue S, Hayasaka Y, Kawaguchi H, Teraoka S, Toma H, Ota K (1996) Clinical pharmacokinetic study of mizoribine in renal transplantation patients. Transplant Proc 28(6):3643\u20133648","journal-title":"Transplant Proc"},{"issue":"4","key":"2584_CR12","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1111\/j.1365-2125.2006.02779.x","volume":"63","author":"D Stypinski","year":"2007","unstructured":"Stypinski D, Obaidi M, Combs M, Weber M, Stewart AJ, Ishikawa H (2007) Safety, tolerability and pharmacokinetics of higher-dose mizoribine in healthy male volunteers. Br J Clin Pharmacol 63(4):459\u2013468. \n                    https:\/\/doi.org\/10.1111\/j.1365-2125.2006.02779.x","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"2584_CR13","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1007\/BF00609886","volume":"24","author":"K Takada","year":"1983","unstructured":"Takada K, Asada S, Ichikawa Y, Sonoda T, Takahara S, Nagano S, Fukunishi T (1983) Pharmacokinetics of bredinin in renal transplant patients. Eur J Clin Pharmacol 24(4):457\u2013461","journal-title":"Eur J Clin Pharmacol"},{"issue":"7","key":"2584_CR14","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1055\/s-0033-1341499","volume":"63","author":"B Ren","year":"2013","unstructured":"Ren B, Fu XH, Zhang ZH, Huang L, Wang CX, Chen X (2013) Determination of mizoribine in human plasma using high-performance liquid chromatography: application to a pharmacokinetic study in Chinese renal transplant recipients. Drug Res 63(7):376\u2013381. \n                    https:\/\/doi.org\/10.1055\/s-0033-1341499","journal-title":"Drug Res"},{"issue":"5","key":"2584_CR15","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1111\/j.1442-200X.2008.02624.x","volume":"50","author":"Y Abe","year":"2008","unstructured":"Abe Y, Mikawa T, Fuke T, Hisano M, Tsuji Y, Watanabe S, Itabashi K (2008) Pharmacokinetic study of mizoribine in child-onset glomerulonephritis. Pediatr Int 50(5):615\u2013619. \n                    https:\/\/doi.org\/10.1111\/j.1442-200X.2008.02624.x","journal-title":"Pediatr Int"},{"issue":"5","key":"2584_CR16","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1111\/j.1442-200x.2004.01936.x","volume":"46","author":"Y Abe","year":"2004","unstructured":"Abe Y, Tsuji Y, Hisano M, Nakada M, Miura K, Watanabe S, Odajima Y, Iikura Y (2004) Pharmacokinetic study of mizoribine in an adolescent with lupus nephritis. Pediatr Int 46(5):597\u2013600. \n                    https:\/\/doi.org\/10.1111\/j.1442-200x.2004.01936.x","journal-title":"Pediatr Int"},{"issue":"4","key":"2584_CR17","first-page":"2111","volume":"26","author":"Y Kokado","year":"1994","unstructured":"Kokado Y, Takahara S, Ishibashi M, Okuyama A (1994) Pharmacokinetics of mizoribine in renal transplant patients. Transplant Proc 26(4):2111\u20132113","journal-title":"Transplant Proc"},{"issue":"4","key":"2584_CR18","first-page":"2029","volume":"26","author":"H Ihara","year":"1994","unstructured":"Ihara H, Shinkuma D, Nojima M, Koike H, Yabumoto H, Yamanaka Y, Ikoma F (1994) Clinical significance of blood level monitoring of mizoribine in kidney transplantation. Transplant Proc 26(4):2029\u20132031","journal-title":"Transplant Proc"},{"issue":"1","key":"2584_CR19","first-page":"1064","volume":"27","author":"P Zaoui","year":"1995","unstructured":"Zaoui P, Serre-Debeauvais F, Bayle F, Bessard G, Pintar P, Deteix P, Janbon B, Vialtel P (1995) Clinical use of mizoribine (Bredinin) and pharmacologic monitoring assessment in renal transplantation. Transplant Proc 27(1):1064\u20131065","journal-title":"Transplant Proc"},{"issue":"1","key":"2584_CR20","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.transproceed.2011.11.015","volume":"44","author":"K Nishimura","year":"2012","unstructured":"Nishimura K, Uchida K, Yuzawa K, Fukuda Y, Ichikawa Y, Akioka K, Fujisawa M, Sugitani A, Ito S, Nakatani T, Horimi T, Yoshimura N (2012) Excellent results with high-dose mizoribine combined with cyclosporine, corticosteroid, and basiliximab in renal transplant recipients: multicenter study in Japan. Transplant Proc 44(1):147\u2013149. \n                    https:\/\/doi.org\/10.1016\/j.transproceed.2011.11.015","journal-title":"Transplant Proc"},{"issue":"3","key":"2584_CR21","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1172\/JCI115101","volume":"87","author":"LA Turka","year":"1991","unstructured":"Turka LA, Dayton J, Sinclair G, Thompson CB, Mitchell BS (1991) Guanine ribonucleotide depletion inhibits T cell activation. Mechanism of action of the immunosuppressive drug mizoribine. J Clin Invest 87(3):940\u2013948. \n                    https:\/\/doi.org\/10.1172\/JCI115101","journal-title":"J Clin Invest"},{"issue":"3","key":"2584_CR22","first-page":"1321","volume":"28","author":"H Ihara","year":"1996","unstructured":"Ihara H, Shinkuma D, Kubo M, Miyamoto I, Nojima M, Koike H, Yabumoto H, Ikoma F (1996) Influence of bioavailability on blood level of mizoribine in kidney transplant recipients. Transplant Proc 28(3):1321\u20131323","journal-title":"Transplant Proc"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-018-2584-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-018-2584-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-018-2584-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T06:22:57Z","timestamp":1572589377000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-018-2584-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,1]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["2584"],"URL":"https:\/\/doi.org\/10.1007\/s00228-018-2584-4","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"type":"print","value":"0031-6970"},{"type":"electronic","value":"1432-1041"}],"subject":[],"published":{"date-parts":[[2018,11,1]]},"assertion":[{"value":"17 August 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the ethics committee of the First Affiliated Hospital of Sun Yat-sen University (approved no: 2015118) and informed consent was obtained from each enrolled patient","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}